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A b s t r a c t
Background: Patients with advanced cancer after radio- and/or chemotherapy are increasingly commonly hospitalised in cardiol-
ogy units due to coexisting cardiovascular diseases (CVD). A rational assessment of mortality risk is an important part of patient 
preparation for invasive cardiac procedures. One disadvantage of cardiac risk scores is the fact that malignancies are not taken 
into account. At present, accurate estimation of life expectancy is possible in up to 20% of patients with an advanced malignancy.
Aim: To evaluate the effect of selected clinical parameters on survival of patients with CVD and coexisting lung or breast 
cancer after radio- and/or chemotherapy. An additional aim was to identify patients with a high probability of surviving a year 
in a good general clinical condition.
Methods: The study group involved 326 subjects with established CVD and lung cancer (small-cell or non-small-cell) or breast 
cancer who were selected from the group of 7818 patients receiving palliative care in the Palium hospice in Czestochowa, 
Poland, in 2008–2012. The obtained data were collected in a database and subjected to a statistical analysis.
Results: The strongest factors associated with an increased risk of death among patients with CVD and coexisting advanced 
lung or breast cancer after chemo- and/or radiotherapy were the type and stage of malignancy, functional status according to 
the ECOG classification, and the presence of cachexia. Other factors that had a significant effect on survival included higher 
severity of heart failure symptoms as evaluated by the New York Heart Association class, decreased left ventricular ejection 
fraction, presence of ischaemic heart disease, chronic obstructive pulmonary disease, fasting hyperglycaemia, and the severity 
of fatigue, nausea, and pain. When the effects of drug treatment on survival were analysed, significantly increased survival 
was observed in patients treated with angiotensin-converting enzyme inhibitors while diuretic and glucocorticosteroid use 
was associated with decreased survival. Among the evaluated groups of patients with CVD and advanced malignancy after 
radio- and/or chemotherapy, the highest probability of surviving a year in a relatively good general clinical condition was noted 
in patients with stage 3 breast cancer without cachexia, ischaemic heart disease and persistent somatic symptoms who were 
treated with tamoxifen, angiotensin-converting enzyme inhibitors and megestrol acetate.
Conclusions: This is the first study that evaluated the combined effect of oncological and cardiovascular risk factors on survival 
of patients with CVD and coexisting cancer after radio- and/or chemotherapy treatment. When the three groups of cancer 
patients with different prognosis were compared, the study revealed varying effects of each factor depending on the underlying 
malignancy. The analysis confirmed the significance of the cumulative risk. The present study showed that malignancy-related 
prognostic factors are important in the context of cardiac evaluation and treatment of cancer patients. It also showed that 
further research is needed to clarify these issues.
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INTRODUCTION
Patients with an advanced cancer after oncologic treatment 
are increasingly commonly hospitalised in cardiology units due 
to coexisting cardiovascular diseases (CVD). Thus, there is an 
increasing need for various invasive procedures, and patient 
selection for invasive treatment becomes more complex. 
A rational assessment of mortality risk is an important part 
of patient preparation for invasive cardiac procedures. This 
is particularly important in case of procedures that lead to 
long-term prognostic benefits.
Life expectancy over 1 year is an important factor when 
choosing the type of cardiac resynchronisation therapy device 
and implanting a cardioverter-defibrillator. As indicated by 
the guidelines, it is also of major importance when selecting 
patient for surgical myocardial revascularisation or transcuta-
neous aortic valve implantation. It is also among major factors 
to be considered when contemplating fibrinolytic therapy for 
acute proximal deep vein thrombosis, and making decisions 
regarding angioplasty and stenting.
In current cardiology practice, mortality risk scores 
have become an essential component of patient selection 
for invasive procedures. The most commonly used cardiac 
risk scores include GRACE, SEATTLE, EuroSCORE, and STS. 
However, these commonly used clinical tools do not include 
malignancy and oncologic treatment in the diagnostic and 
therapeutic process, leading to an increased debate among 
experts regarding limitations of the currently used risk scores 
and the rationale for their improvement and update [1].
Estimation of 1-year survival is most challenging in pa-
tients with an advanced malignancy. At about 1 year before 
dying, a patient with malignancy is usually in a better condition 
than a patient with diabetes, previous stroke, chronic heart 
failure, or chronic obstructive pulmonary disease (COPD), 
while during the terminal month of life, the functional status 
of a patient with malignancy is usually worse compared to pa-
tients with other chronic disease [2]. Patients with an advanced 
malignancy are at an increased risk of adverse cardiovascular 
(CV) outcomes, but their short life expectancy often precludes 
invasive cardiac treatment.
In clinical practice, it is important to answer the question 
whether specific therapy will bring objective benefits including 
prolongation of life and improvement of the quality of life. At 
present, accurate estimation of life expectancy is possible in up 
to 20% of patients with an advanced malignancy [3–5]. Studies 
indicate that patients with an advanced malignancy may be, 
sometimes incorrectly, denied optimal cardiac therapy based 
on underestimated prognostic factors. On the other hand, use 
of too invasive diagnostic and therapeutic procedures, often 
contributing to patient discomfort, may be not justified from 
the ethical point of view.
Careful evaluation of prognostic factors in patients with 
an advanced malignancy treated with radio- and/or chemo-
therapy and concomitant CVD may result in better therapeutic 
and diagnostic decision.
The main aim of the study was to evaluate the effect of 
selected clinical parameters on survival of patients with CVD 
and coexisting lung or breast cancer treated with radio- and/or 
chemotherapy. An additional aim was to identify patients 




We studied 326 patients with established CVD and breast or 
lung cancer (small cell or non-small cell) treated with radio- 
and/or chemotherapy who were selected from the group of 
7818 patients receiving palliative care in the Palium hospice 
in Czestochowa, Poland, in 2008–2012. The patients were 
divided into three groups depending on the underlying malig-
nancy: breast cancer (BC — 99 patients), non-small cell lung 
cancer (NSCLC — 196 patients), and small cell lung cancer 
(SCLC — 31 patients).
Study plan
This prospective case-control study included evaluation of 
survival in the study group in relation to:
 — the type of malignancy and its severity;
 — concomitant CVD including ischaemic heart disease 
(IHD), hypertension, atrial fibrillation, and the severity of 
heart failure symptoms as evaluated using the New York 
Heart Association (NYHA) classification;
 — other common concomitant diseases: COPD, diabetes, 
and fasting hyperglycaemia;
 — selected prognostic factors of an established value in ma-
lignancies: functional status evaluated using the Eastern 
Cooperative Oncology Group (ECOG) scale, somatic fac-
tors such as severity of dyspnoea, pain evaluated using the 
visual analogue scale, severity of nausea, fatigue evaluated 
using the Likert scale, and the presence of cachexia;
 — selected prognostic factors of an established value in 
CVD: resting heart rate and left ventricular ejection 
fraction (LVEF);
 — drug treatment used, including angiotensin-converting 
enzyme inhibitors (ACEI), beta-blockers, megestrol ac-
etate, diuretics, and dexamethasone in all three patient 
groups, and tamoxifen in patients with BC.
The study protocol included: 
 — detailed history;
 — physical examination;
 — blood pressure and heart rate measurements according 
to the European Society of Hypertension guidelines;
 — fasting capillary blood glucose level measurements using 
the Accu-Chek Active glucose meter (device precision in 
accordance with the DIN EN ISO 15197:2003 standard).
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In patients with BC, variables associated with increased 
survival included treatment with ACEI, megestrol acetate, and 
tamoxifen (p < 0.01), while only a nonsignificant trend was 
noted for beta-blocker used compared to non-use.
Analysis of survival predictors in patients with NSCLC and 
CVD is shown in Figure 4.
Reduced survival was associated with more advanced 
malignancy, higher ECOG class, higher severity of somatic 
complaints, higher NYHA class, presence of IHD, higher 
resting heart rate, lower LVEF, fasting hyperglycaemia, con-
comitant COPD, and use of diuretics and dexamethasone.
Prognostic factors in patients with SCLC are shown in 
Figure 5.
In patients with SCLC, factors associated with significantly 
shorter survival included more advanced malignancy, higher 
ECOG class, higher severity of persisting somatic complaints, 
higher heart failure severity as evaluated by the NYHA class, 
presence of IHD, atrial fibrillation, higher resting heart rate, 
lower LVEF, concomitant COPD, non-use of ACEI, and use of 
diuretics. In this patient group, treatment with beta-blockers 
and megestrol acetate was associated with only a trend to-
wards increased survival (p = 0.58).
Patients were evaluated three times: at baseline, after 
3 weeks, and within 7 days before death.
Statistical analysis
Statistical analyses were performed using the SAS package, 
version 9.2 (SAS Institute Inc., Gary, NC), with the level of 
statistical significance at a = 0.05. Normal distribution of 
quantitative variables was verified using the Shapiro-Wilk 
test. Parameters of quantitative variable distribution were 
compared using the Student t test for normally distributed 
variables and the Mann-Whitney U test for non-normally 
distributed variables with categorisation to two groups, and 
analysis of variance for normally distributed variables and the 
Kruskal-Wallis test for non-normally distributed variables with 
categorisation to more than two groups. Univariate survival 
analysis was performed using the Kaplan-Meier approach 
for qualitative descriptors and the Cox regression model for 
quantitative descriptors. Multivariate analysis was used to 
summarise simple univariate analysis using the Cox survival 
analysis with non-proportional hazard function, as the rule 
of proportional hazards, a prerequisite for the proportional 
hazard Cox model, was violated. Calculations were performed 
using a macro prepared for the SAS program. Multivariate 
model included variables with p < 0.02 in univariate analyses, 
with their stepwise elimination until only significant (p < 0.05) 
variables remained in the model.
To evaluate the effect of the evaluated factors on the 
likelihood of surviving at least 1 year, univariate logistic regres-




We studied 326 patients aged 42 to 89 years. The mean 
age of women did not differ significant from that of men 
(67.1 vs. 68.3 years; p = 0.36). No age differences were also 
noted between patients with various malignancies.
Tables below show basic characteristics of the study group 
of patients with a malignancy and concomitant CVD, including 
dichotomous variables (Table 1), ordinal variables (Table 2), 
and quantitative variables (Table 3).
The median survival from the diagnosis of a malignancy 
was 96, 12, and 4.8 months in patients with BC, NSCLC and 
SCLC, respectively (p < 0.01). Patient survival in relation to 
the type of malignancy is shown in Figure 1.
The median survival from admission to the hospice was 
2.5, 1.6, and 1.2 in patients with BC, NSCLC and SCLC, 
respectively (p < 0.01). Patient survival from admission to 
the hospice in relation to the type of malignancy is shown 
in Figure 2.
Multivariate analysis of parameters associated with 
survival in patients with BC and concomitant CVD, with 
corresponding relative hazard values, is shown in Figure 3.
Table 1. Characteristics of the study group including demo-
graphic data, type of malignancy, concomitant conditions,  
and drug treatment used




Type of malignancy: 
Breast cancer 99 (30.5%)
Non-small cell lung cancer 196 (60%)
Small cell lung cancer 31 (9.5%)
Concomitant conditions: 
Ischaemic heart disease 252 (77.3%)
Hypertension 88 (26.9%)








Megestrol acetate 156 (47.8%)
Diuretic 167 (51.2%)
Dexamethasone 162 (49.6%)
ACEI — angiotensin-converting enzyme inhibitor; COPD — chronic 
obstructive pulmonary disease
www.kardiologiapolska.pl



























































































































































































































































































































































































































































































































































































Jarosław Rydzek et al.
734
The presence of coronary artery disease had a significant 
effect on survival in all three groups of patients with an ad-
vanced malignancy. Deaths due to myocardial infarction were 
documented in 6 patients in the study group. Symptomatic 
coronary artery disease may be a reason for, sometimes incor-
rect, denial of appropriate oncologic therapy, while previous 
oncologic therapy may lead to premature coronary artery 
disease [6]. On the other hand, myocardial revascularisation 
may be necessary before appropriate oncologic treatment.
Higher severity of heart failure as evaluated by the NYHA 
class significantly increased mortality among patients with an 
advanced malignancy in our study group. In most patients 
with a history of malignancy who were hospitalised for car-
diac reasons, heart failure resulted from the underlying CVD. 
Drug treatment of heart failure may rapidly reduce its clinical 
symptoms and have a beneficial prognostic effect.
We found no significant effect of hypertension on survival 
in the study group. This might have resulted from a relatively 
short duration of follow-up.
Table 3. Basic descriptive statistics for quantitative data
Parameter (number of observations) Range Mean ± SD Median
LVEF [%] (n = 189) 20–70 36.7 ± 10.9 35
Fasting glucose [mg/dL] (n = 326) 60–330 115.3 ± 43.1 100
Resting heart rate [bpm]:
Measurement 1 (n = 326) 60–130 82.5 ± 13.8 80
Measurement 2 (n = 229) 64–110 82.5 ± 9.4 80
Measurement 3 (n = 219) 68–120 96.4 ± 10 96
Measurements of LVEF and blood glucose were performed at baseline, and heart rate was measured during each visit. LVEF — left ventricular 
fraction; SD — standard deviation
Figure 1. Survival from the diagnosis of malignancy with 95% 
confidence intervals in relation to the type of malignancy;  
BC — breast cancer; NSCLC — non-small cell lung cancer; 
SCLC — small cell lung cancer
Figure 2. Survival from the admission to the hospice in relation 
to the type of malignancy; BC — breast cancer; NSCLC — non-
-small cell lung cancer; SCLC — small cell lung cancer
Our analysis of the study group identified factors associ-
ated with the highest likelihood of surviving 1 year. These 
included the diagnosis of stage III BC, no IHD, grade 1 severity 
of nausea, treatment with tamoxifen, megestrol acetate, and 
ACEI, and non-use of dexamethasone.
DISCUSSION
Malignancy and previous oncologic therapy are factors poten-
tially associated with increased 1-year mortality and should 
be taken into account when selecting patients for invasive CV 
treatment. Appropriate therapeutic decision must be based 
on the cumulative risk related not only to the primary CV 
disorder but also concomitant conditions and symptoms, their 
treatment, and interactions between these factors.
In our study, we compared three groups of patients with 
different malignancies with varying prognosis and showed 
different effects of the evaluated factors depending on specific 
malignancy (Figs. 3–5).
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Figure 3. Hazard ratios (HR) for breast cancer (model including all cases, n = 99); ACEI — angiotensin-converting enzyme inhi-
bitor; COPD — chronic obstructive pulmonary disease; ECOG — Eastern Cooperative Oncology Group; NYHA — New York Heart 
Association; IHD — ischaemic heart disease; LVEF — left ventricular ejection fraction
Figure 4. Hazard ratios (HR) for non-small cell lung cancer (NSCLC) (model including all cases, n = 196); ACEI — angiotensin-
-converting enzyme inhibitor; COPD — chronic obstructive pulmonary disease; ECOG — Eastern Cooperative Oncology Group; 
NYHA — New York Heart Association; IHD — ischaemic heart disease; LVEF — left ventricular ejection fraction
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Most patients with a malignancy show vexing somatic 
symptoms that significantly affect the quality of life [12–14]. 
In our analysis, we found a significant effect of the severity of 
symptoms associated with malignancy, such as fatigue, nausea, 
pain, dyspnoea, and cachexia on survival of patients with an 
advanced malignancy.
Resting heart rate is an established prognostic factor [15, 
16]. A relations between resting heart rate and total and CV 
mortality was found in patients with stable angina, acute 
coronary syndromes, heart failure, stroke, and hypertension. 
LVEF is also an established prognostic factor. A previous study 
suggested that oncologic treatment may lead to impairment of 
left ventricular function [17]. In our study, a significant effect 
of both resting heart rate and LVEF on survival was noted in all 
three patient groups.
Postoperative tamoxifene therapy increases 10-year sur-
vival of BC patients by about 11%. In our analysis, we found 
a significant effect of tamoxifene on survival of BC patients (HR 
0.28). The effect of tamoxifene therapy on the CV system in 
BC patients has also been a subject of a clinical analysis which 
showed a reduction of CV mortality compared to non-users 
[18]. Other metaanalyses also showed a reduced risk of myo-
cardial infarction among women receiving tamoxifene [19, 20].
In our study in patients with CVD and an advanced 
malignancy after oncologic treatment, increased survival was 
noted among patients receiving ACEI. Two key randomised 
trials (CONSENSUS, SOLVD) showed that ACEI treatment 
Atrial fibrillation is associated with twice increased mor-
tality regardless of other established factors contributing to 
mortality [7, 8]. In our analysis, mortality was increased in 
patients with atrial fibrillation but the difference in BC patients 
was not significant.
In a prognostic study of patients with colon cancer and 
diabetes reported by Feng et al. [9], reduced 5-year survival 
was shown in diabetic patients. In our study, a nonsignificant 
trend was noted for an increased mortality among patients 
with diabetes in all three study groups.
Concomitant COPD had a significant effect on reduced 
survival in patients with an advanced malignancy. Lung cancer 
is more common in COPD patients, and COPD is present in 
about half of patients with lung cancer. In addition, broncho-
constriction is a risk factor for lung cancer in non-smokers. In 
an 8-year follow-up study of 5648 Canadian patients, Huiart 
et al. [10] showed then the medical and social burden of 
CVD associated with COPD is greater than that associated 
with COPD itself. Morbidity and mortality was also increased 
compared to the general population.
Most evaluated factors affected the functional status 
of patients with CVD and an advanced malignancy after 
oncologic treatment. A high predictive value of the ECOG 
score in our study reflects the effect of cumulative risk. In 
the study by Schuit et al. [11], functional status was found to 
be the strongest factor affecting survival of patients with an 
advanced malignancy.
Figure 5. Hazard ratios (HR) for small cell lung cancer (SCLC) (n = 31); ACEI — angiotensin-converting enzyme inhibitor;  
COPD — chronic obstructive pulmonary disease; ECOG — Eastern Cooperative Oncology Group; NYHA — New York Heart  
Association; IHD — ischaemic heart disease; LVEF — left ventricular ejection fraction
www.kardiologiapolska.pl
Assessment of risk factors for mortality in patients with CVD and a history of treatment for malignancy
737
reduces mortality among heart failure patients [21, 22]. Early 
ACEI therapy reduces chemotherapy-induced myocardial 
damage and protects from anthracycline cardiomyopathy.
Interestingly, beta-blockers may affect migration of can-
cer cells. Based on laboratory data suggesting an effect of 
beta-blockers on cancer cell mobility and migration, Powe et 
al. [23] performed a study in 466 oncologic patients treated 
with beta-blockers and showed a reduced risk of remote 
metastases and increased 5-year survival among BC patients 
treated with beta-blockers. Also in our study, an increased 
survival among patients treated with beta-blockers was noted 
in all three study groups but this effect was significant only in 
the NSCLC group. When interpreting these results, a relatively 
short duration of follow-up should be taken into account.
In our study, an increased survival was found among 
patients receiving megestrol acetate in the BC (HR 0.16) and 
NSCLC (HR 0.6) group, while only a trend towards increased 
survival was noted among SCLC patients (p = 0.58). Litera-
ture review did not show an effect of megestrol acetate on 
increased survival among patients with malignancy-related 
cachexia, and the effect of this drug on the quality of life 
remains debatable [24].
Interesting data were obtained when we analysed the 
effect of diuretic treatment on survival in patients with CVD 
and an advanced malignancy. In our study, survival among 
patients who required diuretics was significantly reduced 
compared to those patients who were not treated with diuret-
ics. When interpreting these findings, it is likely that patients 
who required diuretic therapy were in a worse general clinical 
condition resulting from more severe heart failure.
Worse survival was noted among BC and NSCLC patients 
who required dexamethasone treatment, while only a trend 
towards reduced survival was noted in SCLC patients. It has 
been reported that dexamethasone may increase cancer cell 
resistance to the cytotoxic effect of oncological drugs [25]. 
However, worse clinical condition of patients treated with 
dexamethasone should be also taken into account when 
interpreting these data.
In summary, we found varying effects of the evaluated 
factors in the three groups of patients with malignancies 
characterised by different prognosis.
Our analysis confirmed the significance of the cumula-
tive risk. The present study showed that malignancy-related 
prognostic factors are important in the context of cardiac 
evaluation and treatment of cancer patients. Further research 
is needed to elucidate these issues more clearly.
Limitations of the study
Our study had several major limitations. A relatively short 
duration of follow-up until death significantly reduced the 
ability to identify the effect of CVD risk factors on survival in 
our patients. In addition, confounding variables, e.g. anaemia, 
and heterogeneity of malignancies might have had a significant 
effect on survival in our study group. Conventional oncologic 
therapy and the response to this treatment clearly affected 
values of the evaluated clinical parameters and prognosis, and 
limited data presented on this issue reflect our focus more 
on cardiac than oncologic aspects. We were unable to verify 
causes of death as autopsies were not performed. Finally, our 
study was an observational one.
CONCLUSIONS
1. Independent predictors of survival of patients with CVD 
and breast or lung cancer after previous oncologic therapy 
include the type of malignancy and its clinical severity.
2. Negative predictors of survival in the study group were 
low ECOG functional status, heart failure severity as 
evaluated by the NYHA classification, significantly re-
duced LVEF, the presence of IHD, fasting hyperglycaemia, 
the presence of COPD, significant fatigue, nausea and 
pain, and the presence of malignancy-related cachexia.
3. Among the evaluated patients with CVD and an advanced 
malignancy after previous chemo- and/or radiotherapy, 
the highest likelihood of 1-year survival in a relatively 
good functional status was noted in patients with breast 
cancer, without cachexia, IHD and persisting somatic 
complaints, who were treated with tamoxifene, ACEI 
and megestrol acetate.
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S t r e s z c z e n i e
Wstęp: Pacjenci z zaawansowanym nowotworem po przebytej terapii onkologicznej coraz częściej są hospitalizowani na 
oddziałach kardiologicznych z powodu schorzeń układu sercowo-naczyniowego. Ważnym elementem przygotowania cho-
rego do procedur inwazyjnych jest racjonalna ocena ryzyka jego zgonu. Wadą stosowanych w kardiologii skal ryzyka jest 
nieuwzględnianie choroby nowotworowej. Prawidłowe oszacowanie prognozowanego czasu przeżycia pacjentów z chorobami 
układu sercowo-naczyniowego i zaawansowaną chorobą nowotworową dotyczy około 20% pacjentów.
Cel: Zasadniczym celem pracy była ocena wpływu wybranych parametrów klinicznych na czas przeżycia u pacjentów z cho-
robą układu sercowo-naczyniowego oraz rakiem płuca lub piersi po przebytym leczeniu onkologicznym. Celem dodatkowym 
była identyfikacja chorych z dużym prawdopodobieństwem przeżycia roku w dobrym stanie ogólnym.
Metody: Badaniem objęto 326 pacjentów z rozpoznaną chorobą układu sercowo-naczyniowego i rakiem piersi lub płuca (drob-
nokomórkowy, niedrobnokomórkowy), wyselekcjonowanych z grupy 7818 chorych, będących w latach 2008–2012 pod opieką 
częstochowskiego hospicjum ,,Palium’’. Otrzymane dane zebrano w arkuszu kalkulacyjnym i poddano analizie statystycznej.
Wyniki: Najsilniejszymi czynnikami zwiększającymi ryzyko zgonu pacjentów z chorobą sercowo-naczyniową oraz zaawan-
sowanym rakiem piersi lub płuca po przebytej chemio- i/lub radioterapii były: rodzaj nowotworu, zaawansowanie choroby 
nowotworowej, stopień upośledzenia sprawności wg ECOG oraz obecność wyniszczenia. Istotny wpływ na skrócenie czasu 
przeżycia miały również: zaawansowanie objawów niewydolności serca wg NYHA, znaczne zmniejszenie frakcji wyrzutowej 
lewej komory, obecność choroby niedokrwiennej serca, obecność przewlekłej obturacyjnej choroby płuc, hiperglikemia 
na czczo, znaczne osłabienie, nudności i ból. W analizie wpływu zastosowanej farmakoterapii na czas przeżycia badanych 
chorych istotnie dłuższe przeżycie zaobserwowano u pacjentów stosujących inhibitory konwertazy angiotensyny (ACE), nato-
miast przyjmowanie diuretyków i steroidów wiązało się z krótszym czasem przeżycia. Największe szanse na roczne przeżycie 
w stosunkowo dobrym stanie funkcjonalnym wśród analizowanych chorych wykazywały pacjentki z rakiem piersi w III stopniu 
zaawansowania klinicznego, bez kacheksji, bez choroby niedokrwiennej serca i uporczywych dolegliwości somatycznych oraz 
poddane terapii tamoksyfenem, inhibitorem ACE i octanem megestrolu.
Wnioski: Wykonana analiza jest pierwszym badaniem oceniającym jednoczesny wpływ na przeżycie kardiologicznych i on-
kologicznych czynników ryzyka u pacjentów z współistniejącym schorzeniem układu sercowo-naczyniowego oraz nowotwo-
rem złośliwym po radio- i/lub chemioterapii. Porównując trzy grupy chorych na nowotwory o zróżnicowanym rokowaniu, 
wykazano odmienny wpływ poszczególnych czynników zależny od choroby podstawowej. Analiza potwierdziła istotność 
ryzyka skumulowanego. W niniejszej pracy pokazano istotne aspekty zastosowania czynników prognostycznych przeżycia 
we współczesnej kardiologii wśród pacjentów z nowotworem, jak również potrzebę przeprowadzenia dalszych badań w celu 
pełniejszego wyjaśnienia omawianych zagadnień.
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